ARCHIVES

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

This article is from The Cancer Letter archive.

Vol. 38 No. 43 | November 16, 2012

Download PDF Visit The Full Archive

Related Articles

Gene Therapy Alters Immune Cells For Treatment Of Advanced Melanoma

September 29, 2006

Obey Convinces House Hew Subcommittee to Cut $17 Million Control, Give It To Bioassays

June 1, 1979

NCI Advisory Group, Other Cancer Meetings

August 16, 1985

CCIRC Holds Groups To 1980 Spending Levels, But They May Get Even Less

January 9, 1981

IOM Calls FDA Advisory System Sounds, Suggests Conflict Criteria Changes

March 5, 1993

Litton’s Government Contracts Status Under Review

September 6, 1985